{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:25Z","timestamp":1786437025278,"version":"build-2736575974"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005721","name":"Universit\u00e4t Bielefeld","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tumor-specific targeting remains a major obstacle for the development of precision cancer therapies. For several tumors and specifically glioblastoma (GBM), an aggressive brain tumor with poor prognosis, more effective treatments are urgently needed. Recombinant adeno-associated viruses (rAAVs), with their established clinical utility and mutational capsid plasticity, offer a promising platform for targeted delivery. We engineered and evaluated modified AAV capsids derived from the established AAV2 with HSPG-tropism knockdown and two less-characterized, tropism-reduced AAV9 variants. The epidermal growth factor receptor (EGFR), a tumor marker often overexpressed in GBM, was targeted by inserting an affibody (Z\n                    <jats:sub>EGFR:1907<\/jats:sub>\n                    ). Also chlorotoxin (CLTX) was inserted, a peptide from scorpion venom reported to bind GBM. Transduction efficiencies were initially assessed with established cell lines (A431, HeLa, U251MG, MCF7). Affibody-displaying capsids exhibited EGFR-dependent transduction, with AAV9-affibody variants surpassing AAV9 wild-type. Several affibody-displaying capsids also transduced patient-derived GBM explants, as confirmed by fluorescence microscopy. These findings highlight the potential of retargeting AAV9 variants and the use of human surgical tissue samples for the initial evaluation of newly designed AAV capsids.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-62481-8","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:47:22Z","timestamp":1786430842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shifting AAV9 tropism by binding moiety insertion enhances transduction of tumor cell lines and human glioblastoma explants"],"prefix":"10.1038","volume":"16","author":[{"given":"Claire","family":"Rothschild-Gronau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Borchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco T.","family":"Radukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Coras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"62481_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. Fidanacogene elaparvovec: First approval. Drugs 84, 479\u2013486 (2024).","journal-title":"Drugs"},{"key":"62481_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","author":"J-H Wang","year":"2024","unstructured":"Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig. Transduct. Target. Ther. 9, 78 https:\/\/doi.org\/10.1038\/s41392-024-01780-w (2024).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"62481_CR3","doi-asserted-by":"publisher","first-page":"10613","DOI":"10.1073\/pnas.90.22.10613","volume":"90","author":"TR Flotte","year":"1993","unstructured":"Flotte, T. R. et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. U S A 90, 10613\u201310617 (1993).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"62481_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier, A. C. et al. Effect of alipogene tiparvovec (AAV1-LPL S447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metabol. 97, 1635\u20131644 (2012).","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"62481_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445\u2013451 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"62481_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/jvi.8.5.766-770.1971","volume":"8","author":"JA Rose","year":"1971","unstructured":"Rose, J. A., Maizel, J. V., Inman, J. K. & Shatkin, A. J. Structural proteins of adenovirus-associated viruses. J. Virol. 8, 766\u2013770 (1971).","journal-title":"J. Virol."},{"key":"62481_CR7","doi-asserted-by":"publisher","first-page":"11556","DOI":"10.1128\/JVI.01536-06","volume":"80","author":"L Govindasamy","year":"2006","unstructured":"Govindasamy, L. et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80, 11556\u201311570 (2006).","journal-title":"J. Virol."},{"key":"62481_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2217\/fvl.13.112","volume":"8","author":"LM Drouin","year":"2013","unstructured":"Drouin, L. M. & Agbandje-McKenna, M. Adeno-associated virus structural biology as a tool in vector development. Future Virol. 8, 1183\u20131199 (2013).","journal-title":"Future Virol."},{"key":"62481_CR9","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1128\/JVI.07232-11","volume":"86","author":"MA DiMattia","year":"2012","unstructured":"DiMattia, M. A. et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947\u20136958 (2012).","journal-title":"J. Virol."},{"key":"62481_CR10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","volume":"72","author":"C Summerford","year":"1998","unstructured":"Summerford, C. & Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438\u20131445 (1998).","journal-title":"J. Virol."},{"key":"62481_CR11","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1128\/JVI.77.12.6995-7006.2003","volume":"77","author":"SR Opie","year":"2003","unstructured":"Opie, S. R., Warrington, K. H., Agbandje-McKenna, M., Zolotukhin, S. & Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995\u20137006 (2003).","journal-title":"J. Virol."},{"key":"62481_CR12","doi-asserted-by":"publisher","first-page":"11072","DOI":"10.1128\/JVI.77.20.11072-11081.2003","volume":"77","author":"A Kern","year":"2003","unstructured":"Kern, A. et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072\u201311081 (2003).","journal-title":"J. Virol."},{"key":"62481_CR13","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1128\/JVI.00448-12","volume":"86","author":"CL Bell","year":"2012","unstructured":"Bell, C. L., Gurda, B. L., Van Vliet, K., Agbandje-McKenna, M. & Wilson, J. M. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J. Virol. 86, 7326\u20137333 (2012).","journal-title":"J. Virol."},{"key":"62481_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","volume":"530","author":"S Pillay","year":"2016","unstructured":"Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108\u2013112 (2016).","journal-title":"Nature"},{"key":"62481_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/mt.2012.186","volume":"21","author":"RC M\u00fcnch","year":"2013","unstructured":"M\u00fcnch, R. C. et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21, 109\u2013118 (2013).","journal-title":"Mol. Ther."},{"key":"62481_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep03759","volume":"4","author":"S Hagen","year":"2014","unstructured":"Hagen, S. et al. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Sci. Rep. 4, 3759 (2014).","journal-title":"Sci. Rep."},{"key":"62481_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/jgm.1392","volume":"11","author":"J Boucas","year":"2009","unstructured":"Boucas, J. et al. Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J. Gene. Med. 11, 1103\u20131113 (2009).","journal-title":"J. Gene. Med."},{"key":"62481_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrg2141","volume":"8","author":"R Waehler","year":"2007","unstructured":"Waehler, R., Russell, S. J. & Curiel, D. T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573\u2013587 (2007).","journal-title":"Nat. Rev. Genet."},{"key":"62481_CR19","doi-asserted-by":"publisher","first-page":"109777","DOI":"10.1016\/j.isci.2024.109777","volume":"27","author":"SG Giannelli","year":"2024","unstructured":"Giannelli, S. G. et al. New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets. iScience 27, 109777 (2024).","journal-title":"iScience"},{"key":"62481_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11011-020-00630-2","volume":"36","author":"D Liu","year":"2021","unstructured":"Liu, D., Zhu, M., Zhang, Y. & Diao, Y. Crossing the blood-brain barrier with AAV vectors. Metab. Brain Dis. 36, 45\u201352 (2021).","journal-title":"Metab. Brain Dis."},{"key":"62481_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"62481_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22, 1073\u20131113 (2020).","journal-title":"Neuro Oncol."},{"key":"62481_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11060-023-04410-7","volume":"164","author":"D Dimov","year":"2023","unstructured":"Dimov, D. et al. The role of cytoreductive surgery in multifocal\/multicentric glioblastomas. J. Neurooncol. 164, 447\u2013459 (2023).","journal-title":"J. Neurooncol"},{"key":"62481_CR24","doi-asserted-by":"publisher","first-page":"C361","DOI":"10.1152\/ajpcell.1993.264.2.C361","volume":"264","author":"JA DeBin","year":"1993","unstructured":"DeBin, J. A., Maggio, J. E. & Strichartz, G. R. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am. J. Physiol. 264, C361-369 (1993).","journal-title":"Am. J. Physiol."},{"key":"62481_CR25","doi-asserted-by":"publisher","first-page":"6882","DOI":"10.1158\/0008-5472.CAN-06-3948","volume":"67","author":"M Veiseh","year":"2007","unstructured":"Veiseh, M. et al. Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 67, 6882\u20136888 (2007).","journal-title":"Cancer Res."},{"key":"62481_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.copbio.2011.06.002","volume":"22","author":"J L\u00f6fblom","year":"2011","unstructured":"L\u00f6fblom, J., Frejd, F. Y. & St\u00e5hl, S. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 22, 843\u2013848 (2011).","journal-title":"Curr. Opin. Biotechnol."},{"key":"62481_CR27","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.febslet.2010.04.014","volume":"584","author":"J L\u00f6fblom","year":"2010","unstructured":"L\u00f6fblom, J. et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584, 2670\u20132680 (2010).","journal-title":"FEBS Lett."},{"key":"62481_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2826.2006.01425.x","volume":"18","author":"T Shah","year":"2006","unstructured":"Shah, T. et al. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol. 18, 355\u2013360 (2006).","journal-title":"J. Neuroendocrinol."},{"key":"62481_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249535","volume":"21","author":"RC Feiner","year":"2020","unstructured":"Feiner, R. C. et al. EGFR-binding peptides: From computational design towards tumor-targeting of adeno-associated virus capsids. Int. J. Mol. Sci. 21, 9535 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"62481_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1236246","volume":"13","author":"X-P Li","year":"2023","unstructured":"Li, X.-P., Guo, Z.-Q., Wang, B.-F. & Zhao, M. EGFR alterations in glioblastoma play a role in antitumor immunity regulation. Front. Oncol. 13, 1236246 (2023).","journal-title":"Front. Oncol."},{"key":"62481_CR31","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.3390\/ijms241311110","volume":"24","author":"SMB Rodriguez","year":"2023","unstructured":"Rodriguez, S. M. B. et al. An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma. IJMS 24, 11110 (2023).","journal-title":"IJMS"},{"key":"62481_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"62481_CR33","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jmb.2007.12.060","volume":"376","author":"M Friedman","year":"2008","unstructured":"Friedman, M. et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J. Mol. Biol. 376, 1388\u20131402 (2008).","journal-title":"J. Mol. Biol."},{"key":"62481_CR34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1021\/acs.biochem.9b00021","volume":"58","author":"RC Feiner","year":"2019","unstructured":"Feiner, R. C., Penn\u00e8, I., M\u00fcller, B. & M\u00fcller, K. M. EGF-mCherry fusion protein expressed in E. coli shows product heterogeneity but a high biological activity. Biochemistry 58, 1043\u20131047 (2019).","journal-title":"Biochemistry"},{"key":"62481_CR35","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1073\/pnas.75.7.3317","volume":"75","author":"H Haigler","year":"1978","unstructured":"Haigler, H., Ash, J. F., Singer, S. J. & Cohen, S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc. Natl. Acad. Sci. U S A. 75, 3317\u20133321 (1978).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"62481_CR36","doi-asserted-by":"publisher","first-page":"9960","DOI":"10.1021\/acs.analchem.5b02572","volume":"87","author":"F Zhang","year":"2015","unstructured":"Zhang, F. et al. Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal. Chem. 87, 9960\u20139965 (2015).","journal-title":"Anal. Chem."},{"key":"62481_CR37","first-page":"903","volume":"41","author":"RM Reilly","year":"2000","unstructured":"Reilly, R. M. et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J. Nucl. Med. 41, 903\u2013911 (2000).","journal-title":"J. Nucl. Med."},{"key":"62481_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41132-w","volume":"14","author":"H Jin","year":"2023","unstructured":"Jin, H. et al. Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation. Nat. Commun. 14, 5417 (2023).","journal-title":"Nat. Commun."},{"key":"62481_CR39","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1021\/acs.biochem.9b00021","volume":"58","author":"RC Feiner","year":"2019","unstructured":"Feiner, R. C., Penn\u00e8, I., M\u00fcller, B. & M\u00fcller, K. M. EGF-mCherry fusion protein expressed in E. coli shows product heterogeneity but a high biological activity. Biochemistry 58, 1043\u20131047 (2019).","journal-title":"Biochemistry"},{"key":"62481_CR40","unstructured":"EGFR protein expression summary. The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000146648-EGFR"},{"key":"62481_CR41","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1172\/JCI57367","volume":"121","author":"CL Bell","year":"2011","unstructured":"Bell, C. L. et al. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121, 2427\u20132435 (2011).","journal-title":"J. Clin. Invest."},{"key":"62481_CR42","doi-asserted-by":"publisher","first-page":"101126","DOI":"10.1016\/j.omtm.2023.101126","volume":"31","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies. Mol. Ther. Methods Clin. Dev. 31, 101126 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"62481_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"62481_CR44","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Q Huang","year":"2024","unstructured":"Huang, Q. et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science 384, 1220\u20131227 (2024).","journal-title":"Science"},{"key":"62481_CR45","doi-asserted-by":"publisher","DOI":"10.1039\/D4AN00404C","author":"M Li","year":"2024","unstructured":"Li, M. et al. Identification of new AAV vectors with enhanced blood\u2013brain barrier penetration efficiency via organ-on-a-chip. Analyst 149, 3980\u20133988 https:\/\/doi.org\/10.1039\/D4AN00404C (2024).","journal-title":"Analyst"},{"key":"62481_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s44161-022-00046-4","volume":"1","author":"T Krolak","year":"2022","unstructured":"Krolak, T. et al. A high-efficiency AAV for endothelial cell transduction throughout the central nervous system. Nat. Cardiovasc. Res. 1, 389\u2013400 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"62481_CR47","doi-asserted-by":"publisher","first-page":"122399","DOI":"10.1016\/j.biomaterials.2023.122399","volume":"303","author":"SA Theuerkauf","year":"2023","unstructured":"Theuerkauf, S. A. et al. AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery. Biomaterials 303, 122399 (2023).","journal-title":"Biomaterials"},{"key":"62481_CR48","doi-asserted-by":"publisher","first-page":"121340","DOI":"10.1016\/j.biomaterials.2021.121340","volume":"281","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain. Biomaterials 281, 121340 (2022).","journal-title":"Biomaterials"},{"key":"62481_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225702","volume":"20","author":"RC Feiner","year":"2019","unstructured":"Feiner, R. C. et al. rAAV engineering for capsid-protein enzyme insertions and mosaicism reveals resilience to mutational, structural and thermal perturbations. Int. J. Mol. Sci. 20, 5702 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"62481_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.omtm.2021.02.019","volume":"21","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. Cell-penetrating peptides enhance the transduction of adeno-associated virus serotype 9 in the central nervous system. Mol. Ther. Methods Clin. Dev. 21, 28\u201341 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"62481_CR51","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1016\/S1525-0016(16)33364-0","volume":"24","author":"TT Duong","year":"2016","unstructured":"Duong, T. T., Vasireddy, V., Merkel, C. E., Bennicelli, J. L. & Bennett, J. 556. Comparative in vitro transduction efficiency of AAV vector serotypes 1\u20139 in different cellular models. Mol. Ther. 24, S222\u2013S223 (2016).","journal-title":"Mol. Ther."},{"key":"62481_CR52","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao, G. et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381\u20136388 (2004).","journal-title":"J. Virol."},{"key":"62481_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/bi00001a003","volume":"34","author":"G Lippens","year":"1995","unstructured":"Lippens, G., Najib, J., Wodak, S. J. & Tartar, A. NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry 34, 13\u201321 (1995).","journal-title":"Biochemistry"},{"key":"62481_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2672","volume":"12","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci. Transl. Med. 12, eaaw2672 (2020).","journal-title":"Sci. Transl. Med."},{"key":"62481_CR55","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1074\/jbc.M205662200","volume":"278","author":"J Deshane","year":"2003","unstructured":"Deshane, J., Garner, C. C. & Sontheimer, H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2*. J. Biol. Chem. 278, 4135\u20134144 (2003).","journal-title":"J. Biol. Chem."},{"key":"62481_CR56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0955-0674(93)90040-W","volume":"5","author":"DE Kleiner","year":"1993","unstructured":"Kleiner, D. E. & Stetler-Stevenson, W. G. Structural biochemistry and activation of matrix metalloproteases. Curr. Opin. Cell. Biol. 5, 891\u2013897 (1993).","journal-title":"Curr. Opin. Cell. Biol."},{"key":"62481_CR57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0092-8674(00)80429-8","volume":"91","author":"Z Werb","year":"1997","unstructured":"Werb, Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91, 439\u2013442 (1997).","journal-title":"Cell"},{"key":"62481_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.matbio.2015.03.004","volume":"44\u201346","author":"Y Itoh","year":"2015","unstructured":"Itoh, Y. Membrane-type matrix metalloproteinases: Their functions and regulations. Matrix Biol. 44\u201346, 207\u2013223 (2015).","journal-title":"Matrix Biol."},{"key":"62481_CR59","doi-asserted-by":"publisher","first-page":"24360","DOI":"10.1074\/jbc.273.38.24360","volume":"273","author":"Y Itoh","year":"1998","unstructured":"Itoh, Y. et al. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface*. J. Biol. Chem. 273, 24360\u201324367 (1998).","journal-title":"J. Biol. Chem."},{"key":"62481_CR60","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1080\/07391102.2016.1231633","volume":"35","author":"H Othman","year":"2017","unstructured":"Othman, H., Wieninger, S. A., ElAyeb, M., Nilges, M. & Srairi-Abid, N. In silico prediction of the molecular basis of ClTx and AaCTx interaction with matrix metalloproteinase-2 (MMP-2) to inhibit glioma cell invasion. J. Biomol. Struct. Dyn. 35, 2815\u20132829 (2017).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"62481_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2023.109981","volume":"399","author":"DM G\u00fcnther","year":"2023","unstructured":"G\u00fcnther, D. M. et al. Substantially improved gene transfer to interneurons with second-generation glutamate receptor-targeted DART-AAV vectors. J. Neurosci. Methods 399, 109981 (2023).","journal-title":"J. Neurosci. Methods"},{"key":"62481_CR62","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/hum.2019.186","volume":"31","author":"AR Batista","year":"2020","unstructured":"Batista, A. R. et al. Ly6a differential expression in blood\u2013brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B. Hum. Gene Ther. 31, 90\u2013102 (2020).","journal-title":"Hum. Gene Ther."},{"key":"62481_CR63","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"62481_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313160","volume":"22","author":"ES Pena","year":"2021","unstructured":"Pena, E. S., Graham-Gurysh, E. G., Bachelder, E. M. & Ainslie, K. M. Design of biopolymer-based interstitial therapies for the treatment of glioblastoma. Int. J. Mol. Sci. 22, 13160 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"62481_CR65","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","volume":"151","author":"RS D\u2019Amico","year":"2021","unstructured":"D\u2019Amico, R. S., Aghi, M. K., Vogelbaum, M. A. & Bruce, J. N. Convection\u2013enhanced drug delivery for glioblastoma: a review. J. Neurooncol. 151, 415\u2013427 (2021).","journal-title":"J. Neurooncol"},{"key":"62481_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","volume":"11","author":"EA Chiocca","year":"2019","unstructured":"Chiocca, E. A. et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).","journal-title":"Sci. Transl. Med."},{"key":"62481_CR67","unstructured":"EU\/3\/16\/. 1786 - orphan designation for treatment of aromatic L-amino acid decarboxylase deficiency | European Medicines Agency. (2024). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-16-1786"},{"key":"62481_CR68","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3390\/cells9081887","volume":"9","author":"R Romano","year":"2020","unstructured":"Romano, R. & Bucci, C. Role of EGFR in the nervous system. Cells 9, 1887 (2020).","journal-title":"Cells"},{"key":"62481_CR69","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/313144a0","volume":"313","author":"TA Libermann","year":"1985","unstructured":"Libermann, T. A. et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144\u2013147 (1985).","journal-title":"Nature"},{"key":"62481_CR70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/14789450.2016.1212665","volume":"13","author":"RC Feiner","year":"2016","unstructured":"Feiner, R. C. & M\u00fcller, K. M. Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Rev. Proteomics 13, 817\u2013832 (2016).","journal-title":"Expert Rev. Proteomics"},{"key":"62481_CR71","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","volume":"23","author":"J Felsberg","year":"2017","unstructured":"Felsberg, J. et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: Prognostic role and comparison between primary and recurrent tumors. Clin. Cancer Res. 23, 6846\u20136855 (2017).","journal-title":"Clin. Cancer Res."},{"key":"62481_CR72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/abio.1998.2725","volume":"261","author":"KM M\u00fcller","year":"1998","unstructured":"M\u00fcller, K. M., Arndt, K. M. & Pl\u00fcckthun, A. Model and simulation of multivalent binding to fixed ligands. Anal. Biochem. 261, 149\u2013158 (1998).","journal-title":"Anal. Biochem."},{"key":"62481_CR73","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/1535-7163.MCT-24-0378","volume":"24","author":"KS Samkoe","year":"2025","unstructured":"Samkoe, K. S. et al. First-in-human study of ABY-029, a Novel fluorescent peptide that targets EGFR, applied to soft-tissue sarcomas. Mol. Cancer Ther. 24, 784\u2013795 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"62481_CR74","unstructured":"ACELYRIN Inc. Psoriatic Arthritis Study of Izokibep, (2022). https:\/\/www.clinicaltrials.gov\/study\/NCT05623345"},{"key":"62481_CR75","unstructured":"Affibody, A. B. A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer; (2025). https:\/\/www.clinicaltrials.gov\/study\/NCT07081555"},{"key":"62481_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/srep03759","volume":"4","author":"S Hagen","year":"2014","unstructured":"Hagen, S. et al. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Sci. Rep. 4, 3759 (2014).","journal-title":"Sci. Rep."},{"key":"62481_CR77","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-025-00837-0","volume":"26","author":"Y Bai","year":"2025","unstructured":"Bai, Y., Pan, Y. & Liu, X. Mechanistic insights into gasdermin-mediated pyroptosis. Nat. Rev. Mol. Cell. Biol. 26, 501\u2013521 (2025).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"62481_CR78","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3463730\/v1","author":"C von Roemeling","year":"2023","unstructured":"von Roemeling, C. et al. CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade. Res. Sq rs 3 rs-3463730. https:\/\/doi.org\/10.21203\/rs.3.rs-3463730\/v1 (2023).","journal-title":"Res. Sq rs 3 rs-3463730"},{"key":"62481_CR79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41586-026-10329-6","volume":"653","author":"U Koeber","year":"2026","unstructured":"Koeber, U. et al. Synthetic super-enhancers enable precision viral immunotherapy. Nature 653, 232\u2013241 (2026).","journal-title":"Nature"},{"key":"62481_CR80","unstructured":"Trogenix ltd. A Phase I\/II Study of an AAV-1 Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma. (2026). https:\/\/clinicaltrials.gov\/study\/NCT07346144"},{"key":"62481_CR81","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice. Mol. Ther. 26, 664\u2013668 (2018).","journal-title":"Mol. Ther."},{"key":"62481_CR82","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182\u2013188 (2018).","journal-title":"Neurosci. Lett."},{"key":"62481_CR83","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ymthe.2019.04.006","volume":"27","author":"LH Vandenberghe","year":"2019","unstructured":"Vandenberghe, L. H. AAV engineering identifies a species barrier that highlights a portal to the brain. Mol. Ther. 27, 901\u2013903 (2019).","journal-title":"Mol. Ther."},{"key":"62481_CR84","unstructured":"Agilent Technologies AAV Helper-Free System Instruction Manual. AAV Helper-Free System (2015). https:\/\/www.agilent.com\/cs\/library\/usermanuals\/Public\/240071.pdf"},{"key":"62481_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1170","volume":"53","author":"MT Radukic","year":"2025","unstructured":"Radukic, M. T. et al. Degradation and stable maintenance of adeno-associated virus inverted terminal repeats in E. coli. Nucleic Acids Res. 53, gkae1170 (2025).","journal-title":"Nucleic Acids Res."},{"key":"62481_CR86","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/cb3002478","volume":"7","author":"MP Hall","year":"2012","unstructured":"Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848\u20131857 (2012).","journal-title":"ACS Chem. Biol."},{"key":"62481_CR87","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1021\/bi0516273","volume":"45","author":"GJ Kremers","year":"2006","unstructured":"Kremers, G. J., Goedhart, J., van Munster, E. B. & Gadella, T. W. J. Cyan and yellow super fluorescent proteins with improved brightness, protein folding, and FRET F\u00f6rster radius. Biochemistry 45, 6570\u20136580 (2006).","journal-title":"Biochemistry"},{"key":"62481_CR88","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62481-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62481-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62481-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:02:31Z","timestamp":1786435351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62481-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62481"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62481-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the responsible Institutional Review Board (Ethikkommission der \u00c4rztekammer Westfalen-Lippe und der Westf\u00e4lischen Wilhelms-Universit\u00e4t M\u00fcnster, Germany, Az 2018-143-f-S, 22 January 2019 & Az 2017-522\u2010f\u2010S, 27 July 2018).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24908"}}